Engineered T Cells for Cancer Treatment

Overview

Journal Cytotherapy

Publisher Elsevier

Specialties Cell Biology
Pharmacology

Date 2013 Nov 19

PMID 24239105

Citations 10

Authors

Usanarat Anurathapan

Ann M Leen

Malcolm K Brenner

Juan F Vera

Affiliations

Soon will be listed here.

Abstract

Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

Citing Articles

Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

Sauerer T, Albrecht L, Sievers N, Gerer K, Hoyer S, Dorrie J Methods Mol Biol. 2024; 2786:219-235.

PMID: 38814397 DOI: 10.1007/978-1-0716-3770-8_10.

T Cell Microvilli: Finger-Shaped External Structures Linked to the Fate of T Cells.

Kim H, Park J, Soh W, Kim N, Moon H, Lee J Immune Netw. 2023; 23(1):e3.

PMID: 36911802 PMC: 9995986. DOI: 10.4110/in.2023.23.e3.

Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches.

Pham T, Coupey J, Candeias S, Ivanova V, Valable S, Thariat J J Exp Clin Cancer Res. 2023; 42(1):50.

PMID: 36814272 PMC: 9945629. DOI: 10.1186/s13046-023-02621-4.

In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.

Naghizadeh A, Tsao W, Cho J, Xu H, Mohamed M, Li D PLoS Comput Biol. 2022; 18(3):e1009883.

PMID: 35303007 PMC: 8955962. DOI: 10.1371/journal.pcbi.1009883.

Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.

Klampatsa A, Leibowitz M, Sun J, Liousia M, Arguiri E, Albelda S Mol Ther Oncolytics. 2020; 18:360-371.

PMID: 32802940 PMC: 7417672. DOI: 10.1016/j.omto.2020.07.005.

References

Kershaw M, Westwood J, Hwu P . Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol. 2002; 20(12):1221-7. DOI: 10.1038/nbt756. View

Ma Q, DeMarte L, Wang Y, Stanners C, Junghans R . Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther. 2004; 11(4):297-306. DOI: 10.1038/sj.cgt.7700685. View

Brown C, Starr R, Aguilar B, Shami A, Martinez C, DApuzzo M . Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012; 18(8):2199-209. PMC: 3578382. DOI: 10.1158/1078-0432.CCR-11-1669. View

Wang J, Press O, Lindgren C, Greenberg P, Riddell S, Qian X . Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004; 9(4):577-86. DOI: 10.1016/j.ymthe.2003.12.011. View

Haynes N, Trapani J, Teng M, Jackson J, Cerruti L, Jane S . Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002; 169(10):5780-6. DOI: 10.4049/jimmunol.169.10.5780. View

Altenschmidt U, Kahl R, Moritz D, Schnierle B, Gerstmayer B, Wels W . Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res. 1996; 2(6):1001-8. View

Lanitis E, Poussin M, Hagemann I, Coukos G, Sandaltzopoulos R, Scholler N . Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2011; 20(3):633-43. PMC: 3293635. DOI: 10.1038/mt.2011.256. View

Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee D . Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2011; 23(5):444-50. PMC: 3360496. DOI: 10.1089/hum.2011.167. View

Vera J, Brenner L, Gerdemann U, Ngo M, Sili U, Liu H . Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33(3):305-15. PMC: 2946348. DOI: 10.1097/CJI.0b013e3181c0c3cb. View

10.

Ramos C, Asgari Z, Liu E, Yvon E, Heslop H, Rooney C . An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010; 28(6):1107-15. PMC: 3290395. DOI: 10.1002/stem.433. View

11.

Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z . Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012; 18(23):6436-45. DOI: 10.1158/1078-0432.CCR-12-1449. View

12.

Yun C, Nolan K, Beecham E, Reisfeld R, Junghans R . Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2001; 2(5):449-59. PMC: 1507984. DOI: 10.1038/sj.neo.7900108. View

13.

Ren-Heidenreich L, Hayman G, Trevor K . Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther. 2000; 11(1):9-19. DOI: 10.1089/10430340050016111. View

14.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

15.

Zhang T, Lemoi B, Sentman C . Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005; 106(5):1544-51. PMC: 1895219. DOI: 10.1182/blood-2004-11-4365. View

16.

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View

17.

Barber A, Zhang T, Megli C, Wu J, Meehan K, Sentman C . Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol. 2008; 36(10):1318-28. PMC: 2638591. DOI: 10.1016/j.exphem.2008.04.010. View

18.

Kowolik C, Topp M, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N . CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006; 66(22):10995-1004. DOI: 10.1158/0008-5472.CAN-06-0160. View

19.

Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G . T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007; 13(12):1440-9. DOI: 10.1038/nm1676. View

20.

Kahlon K, Brown C, Cooper L, Raubitschek A, Forman S, Jensen M . Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004; 64(24):9160-6. DOI: 10.1158/0008-5472.CAN-04-0454. View